Research Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphine

Journal of Biomedical Science

Volumn 17, Issue , 2010, Pages

  Chiang, Yao Chang ^a   Hung, Tsai Wei ^a   Lee, Cynthia Wei Sheng ^a   Yan, Jia Ying ^a   Ho, Ing Kang ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; METHADONE; MORPHINE;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DISEASE MODEL; DRUG TOLERANCE; FEMALE; HEROIN DEPENDENCE; HUMAN; MALE; MORPHINE ADDICTION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RAT; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; BUPRENORPHINE; DISEASE MODELS, ANIMAL; DRUG TOLERANCE; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MORPHINE; MORPHINE DEPENDENCE; PAIN MEASUREMENT; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77956197158     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-46     Document Type: Article

References (44)

1. Results from the 2007 National Survey on Drug Use and Health: National Findings [http://www.oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.pdf]
2. Ostrea EM Jr, Ostrea AR, Simpson PM: Mortality within the first 2 years in infants exposed to cocaine, opiate, or cannabinoid during gestation. Pediatrics 1997, 100:79-83.
3. Yanai J, Huleihel R, Izrael M, Metsuyanim S, Shahak H, Vatury O, Yaniv SP: Functional changes after prenatal opiate exposure related to opiate receptors' regulated alterations in cholinergic innervation. Int J Neuropsychopharmacol 2003, 6:253-265.
4. Ornoy A: The impact of intrauterine exposure versus postnatal environment in neurodevelopmental toxicity: long-term neurobehavioral studies in children at risk for developmental disorders. Toxicol Lett 2003, 140-141:171-181.
5. Topley J, Windsor D, Williams R: Behavioural, developmental and child protection outcomes following exposure to Class A drugs in pregnancy. Child Care Health Dev 2008, 34:71-76.
6. Wilson GS, McCreary R, Kean J, Baxter JC: The development of preschool children of heroin-addicted mothers: a controlled study. Pediatrics 1979, 63:135-141.
7. Trescot AM, Datta S, Lee M, Hansen H: Opioid pharmacology. Pain Physician 2008, 11:S133-153.
8. Pritham UA, Troese M, Stetson A: Methadone and buprenorphine treatment during pregnancy: what are the effects on infants? Nurs Womens Health 2007, 11:558-567.
9. Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000, 67:347-364.
10. Ludlow JP, Evans SF, Hulse G: Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol 2004, 44:302-306.
11. Dryden C, Young D, Hepburn M, Mactier H: Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009, 116:665-671.
12. Lutfy K, Cowan A: Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004, 2:395-402.
13. Sadee W, Rosenbaum JS, Herz A: Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 1982, 223:157-162.
14. Simmat-Durand L, Lejeune C, Gourarier L: Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 2009, 142:119-123.
15. Wright A, Walker J: Drugs of abuse in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001, 15:987-998.
16. Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C: Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 2008, 56:1017-1027.
17. Chiou LC, Yeh GC, Fan SH, How CH, Chuang KC, Tao PL: Prenatal morphine exposure decreases analgesia but not K+ channel activation. Neuroreport 2003, 14:239-242.
18. O'Callaghan JP, Holtzman SG: Prenatal administration of morphine to the rat: tolerance to the analgesic effect of morphine in the offspring. J Pharmacol Exp Ther 1976, 197:533-544.
19. Tao PL, Yeh GC, Su CH, Wu YH: Co-administration of dextromethorphan during pregnancy and throughout lactation significantly decreases the adverse effects associated with chronic morphine administration in rat offspring. Life Sci 2001, 69:2439-2450.
20. Robinson SE, Wallace MJ: Effect of perinatal buprenorphine exposure on development in the rat. J Pharmacol Exp Ther 2001, 298:797-804.
21. Holtman JR Jr, Wala EP: Characterization of the antinociceptive and pronociceptive effects of methadone in rats. Anesthesiology 2007, 106:563-571.
22. Cowan A, Lewis JW, Macfarlane IR: Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977, 60:537-545.
23. Dai X, Brunson CD, Rockhold RW, Loh HH, Ho IK, Ma T: Gender differences in the antinociceptive effect of tramadol, alone or in combination with gabapentin, in mice. J Biomed Sci 2008, 15:645-651.
24. Kirby ML, DeRossett SE, Holtzman SG: Enhanced analgesic response to morphine in adult rats exposed to morphine prenatally. Pharmacol Biochem Behav 1982, 17:1161-1164.
25. Hutchings DE, Zmitrovich AC, Hamowy AS, Liu PY: Prenatal administration of buprenorphine using the osmotic minipump: a preliminary study of maternal and offspring toxicity and growth in the rat. Neurotoxicol Teratol 1995, 17:419-423.
26. Gagin R, Cohen E, Shavit Y: Prenatal exposure to morphine alters analgesic responses and preference for sweet solutions in adult rats. Pharmacol Biochem Behav 1996, 55:629-634.
27. Bhat R, Chari G, Rao R: Effects of prenatal cocaine, morphine, or both on postnatal opioid (mu) receptor development. Life Sci 2006, 78:1478-1482.
28. Rimanoczy A, Vathy I: Prenatal exposure to morphine alters brain mu opioid receptor characteristics in rats. Brain Res 1995, 690:245-248.
29. De Vries TJ, Van Vliet BJ, Hogenboom F, Wardeh G, Van der Laan JW, Mulder AH, Schoffelmeer AN: Effect of chronic prenatal morphine treatment of mu-opioid receptor-regulated adenylate cyclase activity and neurotransmitter release in rat brain slices. Eur J Pharmacol 1991, 208:97-104.
30. Basheer R, Yang J, Tempel A: Chronic prenatal morphine treatment decreases G alpha s mRNA levels in neonatal frontal cortex. Brain Res Dev Brain Res 1992, 70:145-148.
31. Tempel A, Yang J, Basheer R: Prenatal morphine exposure differentially alters expression of opioid peptides in striatum of newborns. Brain Res Mol Brain Res 1995, 33:227-232.
32. Vathy I, Slamberova R, Rimanoczy A, Riley MA, Bar N: Autoradiographic evidence that prenatal morphine exposure sex-dependently alters mu-opioid receptor densities in brain regions that are involved in the control of drug abuse and other motivated behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:381-393.
33. Zagon IS, McLaughlin PJ: Enhanced sensitivity to methadone in adult rats perinatally exposed to methadone. Life Sci 1981, 29:1137-1142.
34. He L, Kim J, Ou C, McFadden W, van Rijn RM, Whistler JL: Methadone antinociception is dependent on peripheral opioid receptors. J Pain 2009, 10:369-379.
35. Davis AM, Inturrisi CE: d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999, 289:1048-1053.
36. Wang C, Pasulka P, Perry B, Pizzi WJ, Schnoll SH: Effect of perinatal exposure to methadone on brain opioid and alpha 2-adrenergic receptors. Neurobehav Toxicol Teratol 1986, 8:399-402.
37. Darmani NA, Schnoll SH, Pandey U, Martin BR: Chronic prenatal methadone exposure alters central opioid mu-receptor affinity in both fetal and maternal brain. Neurotoxicol Teratol 1992, 14:265-271.
38. Grecksch G, Bartzsch K, Widera A, Becker A, Hollt V, Koch T: Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology (Berl) 2006, 186:177-184.
39. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ: Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003, 23:10331-10337.
40. Walker EA, Young AM: Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berl) 2001, 154:131-142.
41. Glover EM, Davis M: Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology (Berl) 2008, 198:167-180.
42. Belcheva MM, Dawn S, Barg J, McHale RJ, Ho MT, Ignatova E, Coscia CJ: Transient down-regulation of neonatal rat brain mu-opioid receptors upon in utero exposure to buprenorphine. Brain Res Dev Brain Res 1994, 80:158-162.
43. Belcheva MM, Bohn LM, Ho MT, Johnson FE, Yanai J, Barron S, Coscia CJ: Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine. Brain Res Dev Brain Res 1998, 111:35-42.
44. Neal CR Jr, Akil H, Watson SJ Jr: Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain. J Chem Neuroanat 2001, 22:219-249.